Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Actinogen Medical ( (AU:ACW) ) has issued an announcement.
Actinogen Medical announced the results of its Annual General Meeting, where all resolutions, including the approval of increased placement capacity, were carried. The company is advancing its clinical trials for Xanamem, a promising treatment for Alzheimer’s and depression, with significant progress in ongoing trials. The XanaMIA Phase 2b/3 trial for Alzheimer’s is set to be fully enrolled by the end of 2025, with initial results expected in early 2026. Actinogen’s efforts in controlling brain cortisol levels through Xanamem have shown promising safety and efficacy in clinical trials, reinforcing its potential impact on the treatment of neurological diseases.
More about Actinogen Medical
Actinogen Medical is an ASX-listed biotechnology company focused on developing novel therapies for neurological and neuropsychiatric diseases linked to dysregulated brain cortisol. Their lead compound, Xanamem, is being developed as a treatment for Alzheimer’s Disease, Depression, and potentially other conditions like Fragile X Syndrome. The company aims to address the substantial unmet medical need for improved treatments for cognitive dysfunction and behavioral abnormalities associated with these diseases.
Average Trading Volume: 3,723,869
Technical Sentiment Signal: Buy
Current Market Cap: A$165.3M
For a thorough assessment of ACW stock, go to TipRanks’ Stock Analysis page.